194 related articles for article (PubMed ID: 28933580)
1. The role of Cediranib in ovarian cancer.
Orbegoso C; Marquina G; George A; Banerjee S
Expert Opin Pharmacother; 2017 Oct; 18(15):1637-1648. PubMed ID: 28933580
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
3. Cediranib in ovarian cancer: state of the art and future perspectives.
Ruscito I; Gasparri ML; Marchetti C; De Medici C; Bracchi C; Palaia I; Imboden S; Mueller MD; Papadia A; Muzii L; Panici PB
Tumour Biol; 2016 Mar; 37(3):2833-9. PubMed ID: 26753963
[TBL] [Abstract][Full Text] [Related]
4. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
5. Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Stark DP; Cook A; Brown JM; Brundage MD; Embleton AC; Kaplan RS; Raja FA; Swart AMW; Velikova G; Qian W; Ledermann JA
Cancer; 2017 Jul; 123(14):2752-2761. PubMed ID: 28339098
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G; Pectasides D
J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in ovarian cancer.
Khalique S; Banerjee S
Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
[TBL] [Abstract][Full Text] [Related]
8. Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.
Decio A; Cesca M; Bizzaro F; Porcu L; Bettolini R; Ubezio P; Taraboletti G; Belotti D; Giavazzi R
Clin Exp Metastasis; 2015 Oct; 32(7):647-58. PubMed ID: 26185056
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
12. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
14. Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
Dizon DS
Am J Clin Oncol; 2013 Oct; 36(5):519-25. PubMed ID: 21552100
[TBL] [Abstract][Full Text] [Related]
15. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
Nikolinakos P; Heymach JV
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S131-4. PubMed ID: 18520296
[TBL] [Abstract][Full Text] [Related]
16. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
Dietrich J; Wang D; Batchelor TT
Expert Opin Investig Drugs; 2009 Oct; 18(10):1549-57. PubMed ID: 19671039
[TBL] [Abstract][Full Text] [Related]
17. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
18. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
Ledermann JA; Embleton-Thirsk AC; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Oza A; Vaughan M; Friedlander M; González-Martín A; Deane E; Popoola B; Farrelly L; Swart AM; Kaplan RS; Parmar MKB;
ESMO Open; 2021 Apr; 6(2):100043. PubMed ID: 33610123
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic agents in ovarian cancer: past, present, and future.
Monk BJ; Minion LE; Coleman RL
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i33-i39. PubMed ID: 27141068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
